On January 10, 2022, PharmaShots has launched a new section in its interview series: Spotlight - Company of the Month

Company of the month is our new exclusive feature under which we are interviewing the key leaders of the start-ups that are providing fierce solutions. We pick one company every month and interview them about their journey, products, and solutions, and upcoming plans. The interview will highlight the company’s innovative activities and technology.

We are starting our Spotlight interview with Chris Dokomajilar, CEO of Deal Forma. Where we discuss the story behind Dealforma, its product, services and new features to be launched in future

DealForma provides comprehensive database and custom analytics covering deal benchmarking and market assessment specifically for the biopharma, medtech, device, and diagnostics sectors. Clients in biotech, global pharma, advisors, and investment banks use DealForma to drive better decisions in less time with highly curated data for deal benchmarking and comparables in licensing deals, partnerships, and acquisitions. The database also includes private and public financings by therapeutic area and stage of funding and direct analyst support. Learn more at dealforma.com

About Chris Dokomajilar:

Chris Dokomajilar is the founder and CEO of DealForma, the comprehensive database and custom analytics service providing deal benchmarking for the biopharma industry. Prior to founding DealForma, Chris held research, management consulting, and industry analytics roles within biopharma and academia at Recap, Deloitte, Thomson Reuters, BioCentury, and the University of California San Francisco. He enjoys the opportunity to contribute to industry thought-leadership and is frequently invited to speak to industry groups about biopharma business development, licensing, and finance. Chris holds a molecular biology degree from the University of California Berkeley.